Precigen (PGEN) to Announce Quarterly Earnings on Tuesday

Precigen (NASDAQ:PGEN) is anticipated to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Precigen to announce earnings of ($0.0121) per share and revenue of $27.9810 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The business had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. On average, analysts expect Precigen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Trading Up 2.5%

Precigen stock traded up $0.15 during trading on Monday, reaching $6.42. The company had a trading volume of 1,103,568 shares, compared to its average volume of 4,434,279. Precigen has a 12-month low of $1.70 and a 12-month high of $6.38. The stock’s 50 day moving average price is $4.98 and its two-hundred day moving average price is $4.41. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -5.40 and a beta of 1.02. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82.

Analyst Upgrades and Downgrades

PGEN has been the subject of several recent research reports. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Precigen in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Finally, Citizens Jmp raised their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.50.

Insider Activity

In related news, CEO Helen Sabzevari sold 346,836 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at $22,198,656.08. This trade represents a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 171,429 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the transaction, the chief financial officer directly owned 354,535 shares in the company, valued at approximately $1,960,578.55. This trade represents a 32.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 922,728 shares of company stock worth $5,028,853 in the last 90 days. 41.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its holdings in Precigen by 216.9% in the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 43,245 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Precigen by 12.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 9,043 shares during the period. Strs Ohio bought a new position in shares of Precigen during the 1st quarter worth about $70,000. Geode Capital Management LLC grew its stake in shares of Precigen by 7.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock valued at $5,325,000 after buying an additional 269,580 shares during the period. Finally, Creative Planning increased its position in Precigen by 127.8% in the 2nd quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 52,901 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.